Why Aralez Pharmaceuticals Inc Jumped Higher Today

What: Aralez Pharmaceuticals (NASDAQ: ARLZ) is up 14% at 3:30 p.m. ET. While there was no obvious news today, investors are likely buying in anticipation of Food and Drug Administration news in the coming month.

So what: The FDA is scheduled to make a decision about Aralez Pharmaceuticals' Yosprala by Sept. 14. That date, called the Prescription Drug User Fee Act (PDUFA) date, is only a goal. The FDA can make a decision before the PDUFA date, so investors are likely jumping in now in anticipation of a decision.

Yosprala is a combination of aspirin and the active ingredient in Procter & Gamble'sPrilosec. Aralez Pharmaceuticals is trying to get the combination approved for the "secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers." In other words, patients who should be taking aspirin for their heart, but can't because the aspirin gives them stomach ulcers.

Aralez is scheduled to report second-quarter earnings next week, but with sales of its current products relatively low -- first-quarter revenue was only $8.1 million -- Aralez will likely continue to trade on sentiment until an FDA decision on Yosprala is revealed.

A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.